Leukemia Journal

Overview

publication venue for

• Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. 2023
• Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. 2021
• Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. 2021
• Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. 2014
• JAK2^V617F impairs lymphoid differentiation in myeloproliferative neoplasms. 2024
• NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia. 2024
• Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity. 2024
• FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia. 2024
• E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. 2023
• Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. 2023
• MAPK-negative feedback regulation confers dependence to JAK2^V617F signaling..  37. 2023
• SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice..  37. 2023
• KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition. 2023
• BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8⁺ T cells. 2023
• Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival. 2022
• Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms. 2022
• CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response..  37. 2022
• Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma..  37. 2022
• MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis..  36. 2021
• Normal life expectancy for polycythemia vera (PV) patients is possible. 2021
• Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS). 2021
• Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy..  35. 2021
• Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. 2021
• Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. 2021
• Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. 2021
• RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators..  35. 2021
• Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. 2021
• Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia..  35. 2021
• Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival..  35. 2021
• Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma..  35. 2021
• Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia..  35. 2021
• Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target..  35. 2021
• U2af1 is required for survival and function of hematopoietic stem/progenitor cells..  35. 2021
• Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML..  34. 2020
• Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS..  35. 2020
• Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study..  34. 2020
• Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin..  35. 2020
• Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response..  35. 2020
• Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era..  34. 2020
• Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study..  35. 2020
• Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study..  34. 2020
• The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK^- anaplastic large cell lymphoma by regulating the DNA helicase HELLS..  34. 2020
• CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition..  34. 2020
• The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment..  34. 2019
• Prognostic impact of RAS-pathway mutations in patients with myelofibrosis..  34. 2019
• Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications..  34. 2019
• Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia..  33. 2019
• Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study..  33. 2019
• Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia..  33. 2019
• Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia..  33. 2019
• Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia..  33. 2019
• A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity..  33. 2019
• Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance..  33. 2019
• Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis..  33. 2019
• TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups..  33. 2019
• LAMP2 expression dictates azacytidine response and prognosis in MDS/AML..  33. 2019
• Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma..  33. 2018
• Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia..  33. 2018
• Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia..  32. 2018
• Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML..  33. 2018
• Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma..  32. 2018
• Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma..  32. 2017
• A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia..  32. 2017
• Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL..  32. 2017
• A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis..  31. 2017
• MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs..  31. 2017
• Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium..  31. 2017
• Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR..  31. 2016
• Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22..  31. 2016
• Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen..  31. 2016
• PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies..  31. 2016
• Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma..  31. 2016
• Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy..  31. 2016
• Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis..  31. 2016
• Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia..  30. 2016
• A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis..  31. 2016
• Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study..  31. 2016
• Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias..  31. 2016
• DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice..  30. 2016
• Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling..  30. 2016
• Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition..  30. 2016
• Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells..  30. 2015
• EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis..  30. 2015
• Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides..  30. 2015
• Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice..  30. 2015
• BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase..  29. 2015
• FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice..  30. 2015
• Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential..  29. 2015
• Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia..  29. 2015
• IL10 receptor is a novel therapeutic target in DLBCLs..  29. 2015
• Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition..  29. 2015
• A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation..  29. 2014
• Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells..  29. 2014
• SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS..  29. 2014
• IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia..  29. 2014
• Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia..  28. 2014
• Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance..  28. 2014
• Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway..  28. 2014
• BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity..  28. 2013
• Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia..  28. 2013
• Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy..  28. 2013
• Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas..  28. 2013
• Toll-like receptor alterations in myelodysplastic syndrome..  27. 2013
• AKT is a therapeutic target in myeloproliferative neoplasms..  27. 2013
• Physiologic corticosterone oscillations regulate murine hematopoietic stem/progenitor cell proliferation and CXCL12 expression by bone marrow stromal progenitors..  27. 2013
• Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity..  27. 2013
• Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells..  27. 2013
• Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis..  27. 2013
• Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety..  27. 2013
• Cell of origin determines clinically relevant subtypes of MLL-rearranged AML..  27. 2012
• Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis..  27. 2012
• PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma..  27. 2012
• MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC..  27. 2012
• A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma..  27. 2012
• miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation..  27. 2012
• Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells..  27. 2012
• Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study..  26. 2012
• Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma..  26. 2012
• Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent..  26. 2012
• Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications..  26. 2012
• Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia..  26. 2011
• The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity..  26. 2011
• The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia..  25. 2011
• NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases..  25. 2010
• PHF6 mutations in adult acute myeloid leukemia..  25. 2010
• IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis..  24. 2010
• A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia..  23. 2009
• Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma..  23. 2009
• Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells..  23. 2009
• Monoclonal antibodies against IREM-1: potential for targeted therapy of AML..  23. 2009
• Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics..  23. 2009
• Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates..  23. 2009
• TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis..  23. 2009
• Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy..  23. 2009
• Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms..  23. 2008
• Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas..  23. 2008
• Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase..  22. 2008
• The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab..  22. 2008
• Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib..  22. 2008
• On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia..  22. 2008
• Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib..  22. 2008
• Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas..  22. 2008
• Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome..  22. 2007
• Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo..  22. 2007
• Genetically identical twin transplantation for chronic lymphocytic leukemia..  21. 2007
• TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations..  21. 2007
• Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements..  21. 2007
• The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines..  21. 2007
• Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib..  21. 2007
• Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma..  21. 2006
• Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein..  20. 2006
• Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2..  20. 2006
• Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells..  20. 2006
• Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome..  20. 2006
• Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome..  20. 2006
• Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation..  20. 2006
• Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia..  19. 2005
• KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)..  19. 2005
• Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate..  18. 2004
• Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group..  18. 2004
• Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study..  18. 2004
• Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha..  17. 2003
• A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia..  17. 2003
• Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate..  17. 2003
• Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity..  17. 2003
• Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195..  17. 2003
• Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones..  16. 2002
• Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo..  16. 2002
• Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies..  16. 2002
• Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission..  15. 2001
• The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells..  14. 2000
• A novel in vitro model of early human adult B lymphopoiesis that allows proliferation of pro-B cells and differentiation to mature B lymphocytes..  14. 2000
• Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy..  14. 2000
• Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4..  14. 2000
• Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid..  13. 1999
• Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis..  13. 1999
• A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia..  12. 1998
• Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia..  11. 1997
• Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission..  11. 1997
• Rapid induction of B-cell lymphomas by avian leukosis virus..  11 Suppl 3. 1997
• Decitabine studies in chronic and acute myelogenous leukemia..  11 Suppl 1. 1997
• Studies of decitabine with allogeneic progenitor cell transplantation..  11 Suppl 1. 1997
• c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells..  10. 1996
• Establishment of AIDS-related lymphoma cell lines from lymphomatous effusions..  10. 1996
• Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice..  10. 1996
• c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia..  10. 1996
• Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia..  10. 1996
• A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemia..  9. 1995
• Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia..  9. 1995
• Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia..  9. 1995
• Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B..  9. 1995
• Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195..  9. 1995
• Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia..  8. 1994
• Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines..  8. 1994
• Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience..  8. 1994
• Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs..  8. 1994
• Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias..  8. 1994
• A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations..  8. 1994
• Phase I-II trial of high dose Ara-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas..  8. 1994
• In vitro establishment of AIDS-related lymphoma cell lines: phenotypic characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection..  7. 1993
• Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease..  7. 1993
• Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLL..  7. 1993
• Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia..  7. 1993
• Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia..  6. 1992
• Homoharringtonine is safe and effective for patients with acute myelogenous leukemia..  6. 1992
• Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia..  5. 1991
• Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia..  5. 1991
• Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination..  5. 1991
• Diffuse large cell lymphoma. Prognostic factors with treatment..  5 Suppl 1. 1991
• Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma..  4. 1990
• Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group..  4. 1990
• Establishment and characterization of two human myeloma cell lines secreting kappa light chains..  3. 1989
• Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia..  3. 1989
• Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia..  3. 1989
• Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195..  3. 1989
• Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol..  3. 1989
• The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia..  2. 1988
• Patterns of T cell receptor gamma gene rearrangement and expression in B and T lymphoid malignancies..  2. 1988
• Juvenile chronic myeloid leukemia: therapeutic insights..  1. 1987
• Diagnosis and monitoring in patients with hairy cell leukemia using the monoclonal antibody anti-HC2..  1. 1987
• Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia..  1. 1987
• The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab..  34. 2019
• A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis..  33. 2019
• Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma..  33. 2019
• A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies..  32. 2017
• Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial..  31. 2016
• The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest..  30. 2016
• In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche..  30. 2015
• Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia..  30. 2015
• A unique aptamer-drug conjugate for targeted therapy of multiple myeloma..  30. 2015
• Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia..  29. 2015
• Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia..  29. 2014
• The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma..  29. 2014
• Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis..  29. 2014
• Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2..  28. 2014
• Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial..  28. 2013
• Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies..  28. 2013
• Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance..  27. 2013
• Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts..  27. 2012
• Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma..  26. 2011
• The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration..  24. 2010
• Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines..  24. 2009
• Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis..  23. 2009
• Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML..  23. 2009
• An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia..  22. 2008
• Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation..  22. 2008
• Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment..  22. 2007
• Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation..  21. 2007
• A novel family of slitrk genes is expressed on hematopoietic stem cells and leukemias..  21. 2007
• JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?.  20. 2006
• NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis..  20. 2006
• Ph-positive and -negative myeloproliferative syndromes may co-exist..  18. 2004
• Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant..  17. 2003
• BRAF gene is not mutated in plasma cell leukemia and multiple myeloma..  17. 2003
• Thalidomide therapy induces response in relapsed mantle cell lymphoma..  17. 2003
• Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera..  17. 2003
• Spotlight on acute promyelocytic leukemia: controversies and challenges..  16. 2002
• Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571..  15. 2001
• Extensive bone marrow necrosis associated with multiple myeloma..  13. 1999
• Discordant erythropoiesis in CML..  12. 1998
• Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? 2005
• Tumor evolution analysis uncovered immune-escape related mutations in relapse of diffuse large B-cell lymphoma. 2024
• CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition. 2023
• Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. 2022
• Risk of disease progression in low-risk MDS is linked to distinct epigenetic subtypes. 2019
• Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. 2019
• Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia. 2017
• Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. 2015
• Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group. 2015
• Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. 2012
• Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells. 2011
• Clinical activity of arsenic trioxide in Burkitt-like lymphoma. 2003
• Chronic myeloid leukemia--some topical issues..  21. 2007
• Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. 2021
• Genome instability in multiple myeloma. 2020
• European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. 2020
• Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. 2017
• Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. 2016
• Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. 2016
• Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). 2014
• New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). 2013
• Clonal evolution in hematological malignancies and therapeutic implications. 2013
• The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics. 2012
• Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. 2012
• Management of treatment-emergent peripheral neuropathy in multiple myeloma. 2011
• International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. 2009
• JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. 2008
• Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. 2007
• Predicting the effect of transcription therapy in hematologic malignancies. 2005
• Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. 2003
• Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. 1993
• Pediatric leukemia/lymphoma with t(8;14)(q24;q11). 1992
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. 2022
• The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. 2018
• Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. 2012
• Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. 2011
• Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. 2003
• Allogeneic and autologous transplantation for chronic lymphocytic leukemia. 2001
• High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease. 1989

Identity

ISO Abbreviation

• Leukemia

Linking ISSN

• 0887-6924

International Standard Serial Number (ISSN)

• 0887-6924

Electronic International Standard Serial Number (EISSN)

• 1476-5551